Author : Manal Kandeel
CoAuthors : Sameeha M. Ali , Mohamed A. Abdelgawad, Mohamed Sadek
Source : Der Pharma Chemica, 2016, 8(1):117-123
Date of Publication : 01/2016
Abstract : Two novel series of 2-(Benzo[d]imidazole/oxazole/thiazole-2-yl))acridine-9(10H)-oneIVa-cand10-(2-((4-
(Benzo[d]imidazole/oxazole/thiazole-2-yl)phenyl)amino)-2-oxoethyl)-9-oxo-9,10-dihydroacridine-4-carboxylic
acidVIIa-cwere synthesized.The antitumor activity of the prepared compounds was evaluated against human breast
cancer (MCF-7), hepatocellular carcinoma (HepG-2) and colon cancer (HCT-116) cell lines using
Sulphorhodamine-B (SRB) assay method.Doxorubicin was used as a reference standard. Most of the tested
compounds showed potent antitumor activity against HCT-116 cell line with IC50 range equal 4-31μM/mland the
compoundVIIcwas the best active one (IC50 = 4.75 μM/ml). VIIashowed the same activity compared to the effect of
the reference drug doxorubicin on Hep-2 cell line(IC50 = 3.75 μM/ml). Allof the tested compoundsshowed weak
activity against MCF-7 cell line(IC50 = 5.01 μM/ml).
Download PDF